Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 5
1989 7
1990 7
1991 7
1992 11
1993 6
1994 6
1995 3
1996 4
1997 8
1998 5
1999 15
2000 15
2001 27
2002 35
2003 34
2004 26
2005 33
2006 51
2007 60
2008 65
2009 74
2010 67
2011 62
2012 63
2013 79
2014 79
2015 61
2016 60
2017 52
2018 38
2019 37
2020 48
2021 52
2022 46
2023 36
2024 61
2025 50
2026 54

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,330 results

Results by year

Filters applied: . Clear all
Page 1
Nebivolol: third-generation beta-blockade.
de Boer RA, Voors AA, van Veldhuisen DJ. de Boer RA, et al. Expert Opin Pharmacother. 2007 Jul;8(10):1539-50. doi: 10.1517/14656566.8.10.1539. Expert Opin Pharmacother. 2007. PMID: 17661735 Review.
Nebivolol is well tolerated by patients with hypertension and heart failure. Although several smaller studies were conducted with nebivolol in hypertensive patients, no large randomised clinical trials have been performed to prove efficacy on hard clinical end point …
Nebivolol is well tolerated by patients with hypertension and heart failure. Although several smaller studies were conducted with …
Pharmacology of nebivolol.
Mangrella M, Rossi F, Fici F, Rossi F. Mangrella M, et al. Pharmacol Res. 1998 Dec;38(6):419-31. doi: 10.1006/phrs.1998.0387. Pharmacol Res. 1998. PMID: 9990650 Review.
Nebivolol is endowed with peripheral vasodilating properties mediated by the modulation of the endogenous production of nitric oxide. ...Nebivolol is quite safe and is well tolerated, also when compared to traditional beta-blockers. ...
Nebivolol is endowed with peripheral vasodilating properties mediated by the modulation of the endogenous production of nitric oxide. …
Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study.
Chang YC, Lee KT, Ho WJ, Ling AW, Chu PH. Chang YC, et al. J Am Heart Assoc. 2026 Feb 3;15(3):e044910. doi: 10.1161/JAHA.125.044910. Epub 2026 Jan 30. J Am Heart Assoc. 2026. PMID: 41614331 Free PMC article.
During a mean follow-up of 4.5 years, nebivolol use was associated with a significantly lower risk of all-cause mortality (hazard ratio [HR], 0.73 [95% CI, 0.63-0.86]) and major adverse cardiovascular events (HR, 0.81 [95% CI, 0.74-0.90]). ...Although these findings sugges …
During a mean follow-up of 4.5 years, nebivolol use was associated with a significantly lower risk of all-cause mortality (hazard rat …
Nebivolol: a review.
Cockcroft J. Cockcroft J. Expert Opin Pharmacother. 2004 Apr;5(4):893-9. doi: 10.1517/14656566.5.4.893. Expert Opin Pharmacother. 2004. PMID: 15102571 Review.
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. ...The effects of nebivolol have been compared with other beta-blockers and also with other classes of antihypertensive agents. ...
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. ...The eff …
Clinical pharmacokinetics of nebivolol: a systematic review.
Hanif N, Zamir A, Imran I, Saeed H, Majeed A, Rehman AU, Ashraf W, Alqahtani F, Rasool MF. Hanif N, et al. Drug Metab Rev. 2023 Nov;55(4):428-440. doi: 10.1080/03602532.2023.2271195. Epub 2023 Oct 28. Drug Metab Rev. 2023. PMID: 37849071
Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabetes mellitus. ...In hypertensive patients, L-nebivolol expressed a higher maximum plasma concentration (C(max)) than D-nebivolol …
Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabete …
Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM. Ritter JM. J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S13-6. doi: 10.1097/00005344-200112003-00003. J Cardiovasc Pharmacol. 2001. PMID: 11811387 Review.
Nebivolol and atenolol have been compared in phenylephrine preconstricted dorsal hand veins of 11 healthy men. ...LNMMA inhibited responses to nebivolol and carbachol to a significantly greater extent than it reduced responses to nitroprusside. ...
Nebivolol and atenolol have been compared in phenylephrine preconstricted dorsal hand veins of 11 healthy men. ...LNMMA inhibited res …
Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
Battise D, Boland CL, Nuzum DS. Battise D, et al. Ann Pharmacother. 2019 Apr;53(4):402-412. doi: 10.1177/1060028018813575. Epub 2018 Nov 18. Ann Pharmacother. 2019. PMID: 30449127 Review.
Another study showed that nebivolol/valsartan had similar additivity scores as compared with other antihypertensive combinations. ...CONCLUSION: Nebivolol/valsartan combination may offer a benefit to patients with an indication for both classes who desire to decreas …
Another study showed that nebivolol/valsartan had similar additivity scores as compared with other antihypertensive combinations. ... …
Nebivolol in the treatment of arterial hypertension.
Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Olawi N, et al. Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):189-201. doi: 10.1111/bcpt.13248. Epub 2019 Jul 4. Basic Clin Pharmacol Toxicol. 2019. PMID: 31066991 Review.
This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third-generation beta-adrenoceptor antagonist (BAA) nebivolol. Furthermore, it reviews the advantages of nebivolol compared to the earlier generation of BAAs with res …
This MiniReview reports the current knowledge about the treatment of arterial hypertension with the third-generation beta-adrenoceptor antag …
Nebivolol: an endothelium-friendly selective beta1-adrenoceptor blocker.
Gao Y, Vanhoutte PM. Gao Y, et al. J Cardiovasc Pharmacol. 2012 Jan;59(1):16-21. doi: 10.1097/FJC.0b013e3182073e27. J Cardiovasc Pharmacol. 2012. PMID: 21283024 Review.
Nebivolol is a racemic mixture of d- and l-isomers. Its beta1-antagonistic properties reside primarily with d-nebivolol although both isomers are capable of increasing the release of NO from the endothelium after binding to beta2- or beta3-adrenergic receptors. ...B …
Nebivolol is a racemic mixture of d- and l-isomers. Its beta1-antagonistic properties reside primarily with d-nebivolol althou …
Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes.
Ginghina ER, Biondi-Zoccai G, Vitali A, Di Napoli LF, Frati G. Ginghina ER, et al. Vascul Pharmacol. 2026 Mar;162:107562. doi: 10.1016/j.vph.2025.107562. Epub 2025 Dec 2. Vascul Pharmacol. 2026. PMID: 41344604 Review.
This review synthesizes current evidence on nebivolol's pharmacologic mechanisms, including its dual action on adrenergic and endothelial pathways, as well as its antioxidant and anti-inflammatory effects. ...Looking ahead, advances in pharmacogenomics, digital phenotyping …
This review synthesizes current evidence on nebivolol's pharmacologic mechanisms, including its dual action on adrenergic and endothe …
1,330 results